Avai Bio 3Q 2026: Revenue $0, EPS ($0.00) — 10-Q Summary

Avai Bio reported no revenue for 3Q 2026, with a net loss of $253,240, a 44% improvement from the prior year. Operating expenses decreased 36% and other expenses fell to zero. The company acquired the Lifestyle Wellness Assessment API for $58,600. Operating cash use declined $122,313 year over year to $489,577 in the six months ended September 30, 2026.

Original reporting
Published Nov 13, 2026, 5:01 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 13, 2026, 5:09 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Avai Bio 3Q 2026: Revenue $0, EPS ($0.00) — 10-Q Summary — source image
Decision brief

The 30-second read

$AVAINeutralLow
01

Why it matters

The filing provides the first public numbers for Q3 2026, showing zero revenue and a narrowed net loss, which may modestly affect the stock price.

02

Market read

Micro‑cap earnings with loss improvement; limited but potentially actionable for short‑term traders.

03

What to watch

The acquisition of a wellness API could signal a strategic pivot that the market has not fully priced in.

Relevance 6/10Novelty 5/10Timing: post‑market filing

Background

Avai Bio is a clinical‑stage biotech focused on metabolic disorders. The 10‑Q reflects ongoing cost reductions and a recent API acquisition.

Company-level read

Ticker impact

$AVAINeutralMedium confidence
Context

Avai Bio filed its 10‑Q showing zero revenue and a narrowed net loss for Q3 2026.

Expected impact

likely slight upward pressure as the market prices in improved loss profile

Evidence & confidence

Micro‑cap earnings with loss improvement often lead to modest price gains, but limited scale keeps impact small.

Market effects

Minimal impact on the broader biotech sector; results reflect company‑specific challenges.

Limited to US micro‑cap investors; no broader regional effect.

Low global relevance given the company's size and niche focus.

Counterpoint

Investors may view the loss narrowing as insufficient without revenue growth, maintaining a bearish stance.

Key entities

  • Avai Bio, Inc.

    Biotech firm reporting its Q3 2026 10‑Q results.

Related articles

$AVAIMedAI 8/10

Avaí Bio Completes Cell Bank Testing, Advances?-Klotho Anti-Aging Therapy

Avaí Bio (AVAI) completed viral and contaminant testing for its GMP Master Cell Bank, confirming it is free of over 30 viruses and other agents. The company, along with Austrianova, is developing a-Klotho-producing cell therapies through their joint venture, Klothonova. The milestone supports further development of the anti-aging therapy. AVAI stock is currently at $0.14, up 21.74%.

$AVAIMedAI 8/10

Replacing Insulin Cells Works. Keeping The Cells Alive Is the Trick

AVAI Bio, Vertex, and Sana are developing treatments for Type 1 diabetes by replacing insulin-producing beta cells. Vertex's trial showed 10/12 patients stopped using insulin, but all require immunosuppression. Sana's gene-edited cells evaded immune detection. AVAI Bio's joint venture, Insulinova, is testing encapsulated beta cells with Ospedale San Raffaele. No trials or timelines have been announced.

$RRGBMedAI 8/10

RED ROBIN GOURMET BURGERS, INC. REPORTS THIRD QUARTER OF FISCAL 2026 RESULTS

RED ROBIN GOURMET BURGERS INC (RRGB) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 RED ROBIN GOURMET BURGERS, INC. REPORTS THIRD QUARTER OF FISCAL 2026 RESULTS Englewood, CO – November 18, 2026 – Red Robin Gourmet Burgers, Inc. (NASDAQ: RRGB) ("Red Robin" or the "Company"), a casual dining restaurant chain serving an innovative selection of high-qu